ArticleEuropean journal of epidemiology2026
Prevalence, characteristics, and projection of long-term childhood cancer survivors in Sweden.
Article in European journal of epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Population-level descriptions of long-term childhood cancer survivors are fundamental to survivorship care and research but seldom available. Accordingly, we aimed to describe long-term childhood cancer survivors at the population-level and project future prevalence. In this register-based study we calculated the absolute number and prevalence proportions of all individuals diagnosed with a childhood cancer (aged 0-14 years, 1958-2018) in Sweden who survived ≥ 5 years post-diagnosis and were alive and residing in Sweden on December 31st, 2023. We also described the clinical and sociodemographic characteristics of this population and presented the observed prevalence over time (1990-2023) and projected prevalence under different mortality assumptions (2024-2040). On December 31st, 2023, there were 8645 long-term childhood cancer survivors in Sweden, equivalent to nearly 1 in 1000 inhabitants (921 persons per million). Leukemias (28.3%) and central nervous system tumors (27.0%) were the most common childhood cancer diagnoses, although the distribution of cancer type varied by attained age. Disease burden in the preceding five years was heterogeneous: approximately 25-30% of the survivors had no recent diagnoses or prescriptions, while a similar proportion experienced substantial morbidity. Most adult survivors were employed (72.0%) and relatively few received sickness benefits (9.7%). From 1990 to 2023, the long-term survivor population tripled in size. Projected mean annual growth was between 1.6% and 2.2%, with the population increasing to approximately 11,400 - 12,600 individuals by 2040. As this heterogeneous population continues growing, our comprehensive description can help plan survivorship care and provide a benchmark for prevalence estimates in settings with less complete data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.